Repository logo

Browsing by Issue Date, starting with "2025-10-03"

Filter results by year or month
Now showing 1 - 1 of 1
  • Development of DNA nanovaccines based on functionalized RALA and Chitosan nanoparticles bearing HPV-16 oncogenes
    Publication . Giusti, Andressa Moreira; Sousa, Ângela Maria Almeida de; Eusébio, Dalinda Isabel da Silva; Cui, Zhengrong
    Cervical cancer (CC), a leading cause of cancer mortality among women, is mainly caused by persistent high-risk human papillomavirus infections, particularly HPV-16 and -18. These viruses possess the oncoproteins E6 and E7, which interfere with p53 and retinoblastoma protein (pRB), respectively, contributing to tumorigenesis. Current vaccines prevent infection but have no therapeutic effect. Moreover, the aggressiveness and lack of specificity of current treatments require innovative targeted therapeutics. DNA vaccines targeting the E6 and E7 oncogenes can be a safer and more promising option for CC eradication, providing preventive and therapeutic effects. The optimal DNA vaccine scenario includes the use of minicircle DNA (mcDNA), a safer and efficient vector than the conventional plasmid DNA (pDNA). So, in this study, we explored the complexation of mcDNA encoding one or both mutated HPV-16 oncogenes (E7mut or E6mut) with biocompatible materials, such as cellpenetrating peptides (CPPs) like RALA, and chitosan (CS). These delivery systems were functionalized with ligands of R8-mannose (R8M), which can enhance DNA delivery and targeting to antigen-presenting cells (APCs). Additionally, we investigated the powder conversion of the DNA/CS-based vaccine using thin-film freeze-drying (TFFD) to enhance vaccine stability. Pure mcDNA (2 µg) was used to optimize the amine-to-phosphate (N/P) ratios of RALA, with and without R8M, and nanoparticles (NPs) were characterized for size, polydispersity index (PDI), zeta potential, complexation efficiency (CE), stability, morphology, and Fourier transform infrared spectroscopy (FTIR). In vitro studies assessed biocompatibility and gene expression in JAWSII dendritic cells after 24 h transfection. For CS-based systems, NPs were prepared with CS, sodium tripolyphosphate (TPP), and 2 µg of parental plasmid (PP)/pDNA or mcDNA encoding both genes, and R8M was also included. The same characterization and biocompatibility assays were performed. Powder conversion of CS NPs was done using TFFD, optimizing conditions for suitable and stable powders. For RALA-based NPs, a N/P ratio of 1.25 was optimal, resulting in homogeneous NPs under 150 nm, negative surface charge, and high CE (>97%). Their morphology was spherical/oval, and incorporation of components was confirmed by FTIR. The NPs were stable under cell culture conditions and biocompatible with JAWSII cells. Expression of the E6 gene was significantly higher in RALA-mannosylated systems, with no differences between the E6mut and multigenic vectors’ gene expression. For CS-based NPs, promising characteristics were obtained, with sizes under 120 nm, homogeneity, positive charges (>20 mV), and CE >98%. Incorporation of PP or mcDNA and R8M did not affect NP properties, indicating feasibility for formulation. The NPs exhibited spherical/oval morphology, and FTIR confirmed the presence of all components. The systems were stable under cell culture conditions and biocompatible with JAWSII cells. Powder conversion of CS-based NPs was optimized with sucrose (1% solid content) as a lyoprotectant, yielding the best results with 0.5 mL per vial. For scale-up with higher NP batches, a solid content of 5.05% with sucrose and leucine was optimal, where R8M incorporation and mcDNA usage showed consistent results, with no changes in NP properties after TFFD. The powders had porous, brittle matrices typical of TFFD. Stability tests over 14 days showed the best result of the powder vaccine at 4°C, supporting improved vaccine storage and distribution in low-resource settings. In conclusion, R8M functionalization enhanced cellular transfection and gene expression in RALA-based systems. Both peptide- and polymer-based delivery systems, with and without R8M, exhibited suitable physicochemical characteristics and biocompatibility. TFFD successfully converted liquid vaccines into stable powders while preserving NPs properties and producing highly porous powders with the potential for good aerosol properties. These findings support further studies exploring intranasal administration for cervical cancer immunization.
    2025-10-03Master thesis Embargoed access Show more